Viking Therapeutics announced the initiation of Part 2 of a maintenance dosing study for VK2735, its dual GLP-1/GIP agonist. The trial will test oral and subcutaneous maintenance regimens after initial weight loss with weekly subcutaneous dosing. Results are expected in 2027.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
